Adults with generalized myasthenia gravis who take Zilbrysq will soon have a second way to give themselves their daily dose. The FDA approved a once-daily autoinjector version of the drug, which delivers a preset dose when pressed against the skin, drugmaker UCB announced on Oct. 16.
The autoinjector will not reach pharmacies right away. UCB expects it to become commercially available in the first quarter of 2027. Until then, patients will continue using the existing prefilled syringe.
For people living with a disease that can weaken the hands, the arms, and even the muscles used for breathing, how a daily shot is given matters. A device that needs less grip or fewer steps can make the difference between injecting alone and waiting for a caregiver. Still, the approval changes the device, not the medicine, its risks, or who is eligible to receive it.
A Device Change, Not a New Drug
Myasthenia gravis is a rare autoimmune disease in which the immune system disrupts signals between nerves and muscles. Symptoms can include drooping eyelids, double vision, trouble chewing, swallowing, or speaking, and, in severe cases, dangerous breathing weakness. UCB cites a global prevalence of 150 to 350 cases per 1 million people.
Zilbrysq, known generically as zilucoplan, is approved for adults whose blood tests show antibodies against the acetylcholine receptor. It blocks complement component 5, a protein involved in immune damage where nerves meet muscles, though exactly how it eases symptoms is not known. The FDA first approved the drug in 2023, and its dose depends on body weight, according to the agency’s Drug Trials Snapshot.
The new approval rests on three studies. In a study of 14 healthy volunteers, the autoinjector delivered the drug equivalently to the syringe. In a Phase 3b study of 31 adults with the disease, 99.8% of 449 autoinjectors used and returned delivered a complete dose. In a usability study of 100 participants, including patients, caregivers, and health care professionals, 90% completed an injection on their first try without training.
“For a chronic condition like gMG, having different administration options allows patients to choose the approach that best fits their individual preferences and routines,” said Donatello Crocetta, UCB’s global head of medical affairs and chief medical officer.
MedicalDaily Evidence Check: These were small, open-label, company-sponsored device studies designed to show the autoinjector delivers the same drug reliably. They were not designed to show the autoinjector works better than the syringe. Injection-site pain was the most common side effect in the Phase 3b study, affecting 3 of 31 patients, according to Practical Neurology.
The Boxed Warning Still Applies
The new device does not change Zilbrysq’s most serious risk. The drug carries a boxed warning, the FDA’s strongest, for life-threatening and fatal meningococcal infections, which can cause meningitis and bloodstream infection. Patients must complete or update meningococcal vaccines for serogroups A, C, W, Y, and B at least two weeks before the first dose, unless delaying treatment poses a greater risk.
Because of that risk, Zilbrysq is available only through a restricted safety program called the Zilbrysq REMS, which requires prescribers to enroll, counsel patients, and make sure they are vaccinated. According to the label, patients remain at increased risk even after vaccination.
The label also warns about other serious infections, including those caused by gonorrhea and pneumococcal bacteria, and about pancreatitis and pancreatic cysts. Doctors are told to check pancreatic enzyme levels before treatment begins. The most common side effects in the main clinical trial were injection-site reactions, upper respiratory infections, and diarrhea.
Patients and caregivers should know the warning signs of meningococcal infection, which can become deadly within hours. Fever, headache, stiff neck, confusion, nausea, vomiting, sensitivity to light, cold hands and feet, rapid breathing, or a dark purple rash need emergency care right away, according to CDC’s meningococcal disease symptoms page. Severe belly pain could signal pancreatitis, and new trouble breathing or swallowing may indicate a myasthenic crisis that requires a call to 911.
Insurance, Timing, and Switching Devices
Patients who use the prefilled syringe and want to try the autoinjector should talk with their neurologist about how and when to switch once it launches. Training from a nurse or pharmacist is still worth requesting, even though most usability participants succeeded without it.
Coverage may take work. Insurers often require prior authorization for Zilbrysq. A Blue Cross NC policy, for example, requires documentation of symptom severity and either a trial of standard treatments or a reason they cannot be used. Patients can ask whether a new device form triggers a fresh review and whether manufacturer support programs can help with costs.
Dexterity is another practical factor. Some people with weak hands may find one device easier than the other, and caregivers who give the injection can weigh in. Patients should not stop daily doses while waiting for the autoinjector, and any change in device should be planned with the prescribing neurologist.
The next milestone is the commercial launch in early 2027. Until then, patients who want the autoinjector can ask their neurologist to note the preference so the switch can happen quickly once pharmacies stock it.
Key Questions Answered
What did the FDA approve? A once-daily autoinjector for Zilbrysq, for adults with generalized myasthenia gravis who test positive for acetylcholine receptor antibodies.
When will it be available? UCB expects it to reach the U.S. market in the first quarter of 2027.
Is it a new medicine? No. It is the same drug in a new device. The prefilled syringe remains available.
What is the biggest safety concern? A boxed warning for serious meningococcal infections. Patients need meningococcal vaccines before starting treatment.
What symptoms need emergency care? Fever, headache, stiff neck, confusion, a dark purple rash, or new trouble breathing or swallowing.
Will insurance cover it? Coverage varies. Many insurers require prior authorization, so patients should check with their plan before switching.
Published by Medicaldaily.com
